The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
Chemical Compound Review

Chinazolin     quinazoline

Synonyms: Phenmiazine, QUINAZOLINE, SureCN5920, CHEMBL301359, ACMC-1CHK9, ...
Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of quinazoline


High impact information on quinazoline


Chemical compound and disease context of quinazoline


Biological context of quinazoline


Anatomical context of quinazoline


Associations of quinazoline with other chemical compounds


Gene context of quinazoline


Analytical, diagnostic and therapeutic context of quinazoline


  1. Quinazoline-derived alpha1-adrenoceptor antagonists induce prostate cancer cell apoptosis via an alpha1-adrenoceptor-independent action. Benning, C.M., Kyprianou, N. Cancer Res. (2002) [Pubmed]
  2. Hemodynamic responsiveness to short- and long-acting vasodilators in left ventricular failure. Franciosa, J.A., Cohn, J.N. Am. J. Med. (1978) [Pubmed]
  3. Clinical pharmacology of selective alpha blockers. Hemodynamics and effects on lipid levels. Reid, J.L., Elliott, H.L., Vincent, J., Meredith, P.A. Am. J. Med. (1987) [Pubmed]
  4. 4-(3'-Bromo-4'hydroxylphenyl)-amino-6,7-dimethoxyquinazoline: a novel quinazoline derivative with potent cytotoxic activity against human glioblastoma cells. Narla, R.K., Liu, X.P., Myers, D.E., Uckun, F.M. Clin. Cancer Res. (1998) [Pubmed]
  5. Potent in vitro and in vivo antitoxoplasma activity of the lipid-soluble antifolate trimetrexate. Allegra, C.J., Kovacs, J.A., Drake, J.C., Swan, J.C., Chabner, B.A., Masur, H. J. Clin. Invest. (1987) [Pubmed]
  6. 5-HT2-receptor blockade in the treatment of heart failure. A preliminary study. Demoulin, J.C., Bertholet, M., Soumagne, D., David, J.L., Kulbertus, H.E. Lancet (1981) [Pubmed]
  7. Diverse small-molecule modulators of SMN expression found by high-throughput compound screening: early leads towards a therapeutic for spinal muscular atrophy. Jarecki, J., Chen, X., Bernardino, A., Coovert, D.D., Whitney, M., Burghes, A., Stack, J., Pollok, B.A. Hum. Mol. Genet. (2005) [Pubmed]
  8. AZD2171: a highly potent, orally bioavailable, vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor for the treatment of cancer. Wedge, S.R., Kendrew, J., Hennequin, L.F., Valentine, P.J., Barry, S.T., Brave, S.R., Smith, N.R., James, N.H., Dukes, M., Curwen, J.O., Chester, R., Jackson, J.A., Boffey, S.J., Kilburn, L.L., Barnett, S., Richmond, G.H., Wadsworth, P.F., Walker, M., Bigley, A.L., Taylor, S.T., Cooper, L., Beck, S., Jürgensmeier, J.M., Ogilvie, D.J. Cancer Res. (2005) [Pubmed]
  9. Platelet-derived growth factor (PDGF) autocrine signaling regulates survival and mitogenic pathways in glioblastoma cells: evidence that the novel PDGF-C and PDGF-D ligands may play a role in the development of brain tumors. Lokker, N.A., Sullivan, C.M., Hollenbach, S.J., Israel, M.A., Giese, N.A. Cancer Res. (2002) [Pubmed]
  10. Maspin sensitizes prostate cancer cells to doxazosin-induced apoptosis. Tahmatzopoulos, A., Sheng, S., Kyprianou, N. Oncogene (2005) [Pubmed]
  11. Computational study of antagonist/alpha1A adrenoceptor complexes--observations of conformational variations on the formation of ligand/receptor complexes. Kinsella, G.K., Rozas, I., Watson, G.W. J. Med. Chem. (2006) [Pubmed]
  12. Inhibition of the growth of human hepatocellular carcinoma in vitro and in athymic mice by a quinazoline inhibitor of thymidylate synthase, CB3717. Curtin, N.J., Harris, A.L., James, O.F., Bassendine, M.F. Br. J. Cancer (1986) [Pubmed]
  13. Anoikis induction by quinazoline based alpha 1-adrenoceptor antagonists in prostate cancer cells: antagonistic effect of bcl-2. Keledjian, K., Kyprianou, N. J. Urol. (2003) [Pubmed]
  14. Structural studies on bio-active compounds. Part 9. 2,4-Diamino-6-azidoquinazoline hydrochloride. Schwalbe, C.H., King, M.E., Wong, K.P., Lambert, P.A., Bliss, A., Stevens, M.F. Anticancer Drug Des. (1987) [Pubmed]
  15. ICI D1694, a quinazoline antifolate thymidylate synthase inhibitor that is a potent inhibitor of L1210 tumor cell growth in vitro and in vivo: a new agent for clinical study. Jackman, A.L., Taylor, G.A., Gibson, W., Kimbell, R., Brown, M., Calvert, A.H., Judson, I.R., Hughes, L.R. Cancer Res. (1991) [Pubmed]
  16. Effect of direct suppression of thymidylate synthase at the 5,10-methylenetetrahydrofolate binding site on the interconversion of tetrahydrofolate cofactors to dihydrofolate by antifolates. Influence of degree of dihydrofolate reductase inhibition. Seither, R.L., Trent, D.F., Mikulecky, D.C., Rape, T.J., Goldman, I.D. J. Biol. Chem. (1991) [Pubmed]
  17. Inhibition of human glioblastoma cell adhesion and invasion by 4-(4'-hydroxylphenyl)-amino-6,7-dimethoxyquinazoline (WHI-P131) and 4-(3'-bromo-4'-hydroxylphenyl)-amino-6,7-dimethoxyquinazoline (WHI-P154). Narla, R.K., Liu, X.P., Klis, D., Uckun, F.M. Clin. Cancer Res. (1998) [Pubmed]
  18. Alfuzosin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in benign prostatic hyperplasia. Wilde, M.I., Fitton, A., McTavish, D. Drugs (1993) [Pubmed]
  19. Rational design of quinazoline-based irreversible inhibitors of human erythrocyte purine nucleoside phosphorylase. Dempcy, R.O., Skibo, E.B. Biochemistry (1991) [Pubmed]
  20. Apoptotic impact of alpha1-blockers on prostate cancer growth: a myth or an inviting reality? Tahmatzopoulos, A., Kyprianou, N. Prostate (2004) [Pubmed]
  21. Other secondary sequelae of treatments for myeloproliferative disorders. Gilbert, H.S. Semin. Oncol. (2002) [Pubmed]
  22. Prevention of hippocampus neuronal damage in ischemic gerbils by a novel lipid peroxidation inhibitor (quinazoline derivative). Hara, H., Kogure, K. J. Pharmacol. Exp. Ther. (1990) [Pubmed]
  23. Time dependence of DNA lesions and growth inhibition by ICI D1694, a new quinazoline antifolate thymidylate synthase inhibitor. Yin, M.B., Guimaraes, M.A., Zhang, Z.G., Arredondo, M.A., Rustum, Y.M. Cancer Res. (1992) [Pubmed]
  24. Locus of the interaction among 5-fluorouracil, leucovorin, and interferon-alpha 2a in colon carcinoma cells. Houghton, J.A., Morton, C.L., Adkins, D.A., Rahman, A. Cancer Res. (1993) [Pubmed]
  25. Biochemical and antitumor effects of 5,8-dideazaisopteroylglutamate, a unique quinazoline inhibitor of thymidylate synthase. Fernandes, D.J., Bertino, J.R., Hynes, J.B. Cancer Res. (1983) [Pubmed]
  26. Reversible G(1) arrest induced by inhibition of the epidermal growth factor receptor tyrosine kinase requires up-regulation of p27(KIP1) independent of MAPK activity. Busse, D., Doughty, R.S., Ramsey, T.T., Russell, W.E., Price, J.O., Flanagan, W.M., Shawver, L.K., Arteaga, C.L. J. Biol. Chem. (2000) [Pubmed]
  27. A novel approach in the treatment of cancer: targeting the epidermal growth factor receptor. Ciardiello, F., Tortora, G. Clin. Cancer Res. (2001) [Pubmed]
  28. Signaling-inactive epidermal growth factor receptor/ligand complexes in intact carcinoma cells by quinazoline tyrosine kinase inhibitors. Lichtner, R.B., Menrad, A., Sommer, A., Klar, U., Schneider, M.R. Cancer Res. (2001) [Pubmed]
  29. Quinazoline-based alpha 1-adrenoceptor antagonists induce prostate cancer cell apoptosis via TGF-beta signalling and I kappa B alpha induction. Partin, J.V., Anglin, I.E., Kyprianou, N. Br. J. Cancer (2003) [Pubmed]
  30. Rescue of DeltaF508 and other misprocessed CFTR mutants by a novel quinazoline compound. Loo, T.W., Bartlett, M.C., Clarke, D.M. Mol. Pharm. (2005) [Pubmed]
  31. Targeting aurora2 kinase in oncogenesis: a structural bioinformatics approach to target validation and rational drug design. Vankayalapati, H., Bearss, D.J., Saldanha, J.W., Muñoz, R.M., Rojanala, S., Von Hoff, D.D., Mahadevan, D. Mol. Cancer Ther. (2003) [Pubmed]
  32. Inhibition of ALK enzymatic activity in T-cell lymphoma cells induces apoptosis and suppresses proliferation and STAT3 phosphorylation independently of Jak3. Marzec, M., Kasprzycka, M., Ptasznik, A., Wlodarski, P., Zhang, Q., Odum, N., Wasik, M.A. Lab. Invest. (2005) [Pubmed]
  33. Tyrosine kinase inhibitors. 15. 4-(Phenylamino)quinazoline and 4-(phenylamino)pyrido[d]pyrimidine acrylamides as irreversible inhibitors of the ATP binding site of the epidermal growth factor receptor. Smaill, J.B., Palmer, B.D., Rewcastle, G.W., Denny, W.A., McNamara, D.J., Dobrusin, E.M., Bridges, A.J., Zhou, H., Showalter, H.D., Winters, R.T., Leopold, W.R., Fry, D.W., Nelson, J.M., Slintak, V., Elliot, W.L., Roberts, B.J., Vincent, P.W., Patmore, S.J. J. Med. Chem. (1999) [Pubmed]
  34. In vitro and in vivo activity of 2,4-diamino-6-(2-(3,4-dichlorophenyl)acetamido) quinazoline against Cryptococcus neoformans. Hariri, A.R., Larsh, H.W. Proc. Soc. Exp. Biol. Med. (1976) [Pubmed]
  35. Immunoreactive dUMP and TTP pools as an index of thymidylate synthase inhibition; effect of tomudex (ZD1694) and a nonpolyglutamated quinazoline antifolate (CB30900) in L1210 mouse leukaemia cells. Aherne, G.W., Hardcastle, A., Raynaud, F., Jackman, A.L. Biochem. Pharmacol. (1996) [Pubmed]
  36. Determination of the imidazo quinazoline derivative Ro 13-6438 in biological fluids by high-performance liquid chromatography. Haefelfinger, P., Hess, B. J. Chromatogr. (1984) [Pubmed]
  37. Development of a high-throughput robotic fluorescence-based assay for HsEg5 inhibitor screening. Zhang, B., Senator, D., Wilson, C.J., Ng, S.C. Anal. Biochem. (2005) [Pubmed]
WikiGenes - Universities